Skip to main content
. Author manuscript; available in PMC: 2020 Apr 24.
Published in final edited form as: Oncogene. 2018 Sep 3;38(5):716–730. doi: 10.1038/s41388-018-0461-3

Figure 2. Stromal heterogeneity dictates tumor progression.

Figure 2.

(A) Pie charts illustrate the relative ratio of the indicated stromal fibroblastic populations based on cell surface expression of the indicated markers: CD90+/CD105+ (blue), CD90+/Stro-1+ (purple), CD90+/CD117+ (red), and CD90− (green), n > 3. ANOVA analysis demonstrates NAF, CAF, and CAFHiP have distinct populations (p < 0.03). (B) Scatter plot indicates individual tumor volume (log transformed) for tissue recombinant tumors made up of 22Rv1 epithelia with the indicated fibroblastic populations. n > 4. (C) Histology for representative recombinant tumor sections of 22Rv1 with the indicated fibroblastic populations are shown. H&E staining shows tumor morphology (scale bar represents 64 μm). Ki67 and TUNEL immune-localization, with hematoxylin nuclear counterstain (scale bar represents 32 μm), is shown, n > 5. (D) The scatter plot shows quantitation of percent expression for Ki67 immunohistochemical staining, n > 8. (E) The scatter plot shows quantitation of the number of TUNEL positive nuclei per field by immunohistochemical staining, n > 5. For all, error bars are mean +/− SD, and p values of less than 0.05 were considered statistically significant (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).